Market News

EPS for Summit Therapeutics plc (SMMT) Expected At $-0.15

Summit Therapeutics plc (NASDAQ:SMMT) Logo

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.15 EPS on December, 5.They anticipate $0.05 EPS change or 25.00 % from last quarter’s $-0.2 EPS. After having $2.10 EPS previously, Summit Therapeutics plc’s analysts see -107.14 % EPS growth. The stock decreased 1.29% or $0.02 during the last trading session, reaching $1.53. About 12,626 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has declined 86.01% since November 9, 2017 and is downtrending. It has underperformed by 101.63% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 3 analysts covering Summit Therapeutics (NASDAQ:SMMT), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Summit Therapeutics had 3 analyst reports since June 27, 2018 according to SRatingsIntel. The rating was downgraded by Oppenheimer on Wednesday, June 27 to “Hold”. The firm has “Neutral” rating by Janney Capital given on Thursday, June 28. The company was downgraded on Wednesday, June 27 by SunTrust.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $26.78 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It has a 0.79 P/E ratio. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: which released: “Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference” on November 07, 2018, also with their article: “The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug” published on November 02, 2018, published: “Summit Recognises C. difficile Awareness Month” on November 01, 2018. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: and their article: “Award of Share Options” published on October 22, 2018 as well as‘s news article titled: “Summit Therapeutics to Participate in Upcoming Investor Events” with publication date: October 10, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *